Bridging the Gap: Enhancing Cancer Care for Underserved Populations With the Veris Health Cancer Care Platform
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorVERIS HEALTH INC
About this trial
The proposed study aims to optimize and validate the Veris Cancer Care Platform for the needs of medically underserved cancer patients receiving outpatient cancer therapy. The Veris Health platform is a remote patient monitoring and communication system designed to bridge the gap between clinical visits and provide oncology care teams with objective data during high-risk periods.
This study will specifically focus on optimizing the Veris Health platform for patients with language barriers, limited access to technology, and socioeconomic disparities. By incorporating user-centered design and working closely with community health centers, the research team will ensure that the platform is culturally and linguistically appropriate, easy to use, and accessible for all patients.
The study will use a mixed-methods approach to validate the effectiveness of the optimized platform, including quantitative data analysis and qualitative interviews with patients and healthcare providers. The goal is to demonstrate the potential for the Veris Health platform to improve outcomes for vulnerable populations by reducing hospitalizations, emergency department visits, and the economic burden of cancer care.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults > 18 years old
Diagnosis of cancer
ECOG Performance Status of 0-2
Undergoing or initiating systemic anticancer therapy
Disqualifiers
None
Trial population
Underserved population undergoing Cancer treatment with at least one on the following barriers to healthcare access: Spanish as primary language, uninsured, insured with Medicaid, dual eligible for Medicare and Medicaid.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Veris Health Inc. Application
Other interventionVeris Health offers at-home devices to monitor multiple physiological parameters, including temperature, heart rate, oxygen saturation, blood pressure, weight, and activity (step count). Patients are provided with a home cellular hub that is already paired to peripheral devices via Bluetooth. The hub communicates with all devices and the local cellular network out-of-the-box, and data is automatically sent via cellular network to the Veris Health backend database, making it easy for patients to use the system. Patients are responsible for taking their vital sign measurements daily. The devices automatically send the measurement data to the Veris Health HIPAA compliant, secure cloud server via the preconnected cellular hub.
Treatment groups
50 Participants
are divided into 1 treatment groupGroup A: Main Phase group1 intervention
Trial outcomes
Primary outcomes
1
Usability of the Veris Health Cancer Care Platform
Usability of the Veris Health Cancer Care platform as assessed by the Software Usability Measurement Inventory (SUMI) among patients, caretakers, and healthcare teams. Measure: SUMI total and domain scores Time Frame: During study participation
Time frame
5 Months2
Product Design Usability and Acceptability
Ease of use, accessibility, and acceptability of the Veris Health Cancer Care platform based on A/B testing of product design features. Measure: Comparative usability metrics (e.g., task completion success, user preference) Time Frame: During study participation
Time frame
5 Months3
User Needs and Preferences
User-identified needs, preferences, and barriers to use of the Veris Health Cancer Care platform. Measure: Qualitative themes derived from user interviews and focus groups Time Frame: During study participation
Time frame
5 MonthsSecondary outcomes
1
Health-Related Quality of Life (HRQL)
Change in health-related quality of life among participants using the Veris Health Cancer Care platform. Measure: EQ-5D Index score
Time frame
5 Months2
Symptom Burden of Cancer Treatment Side Effects
Frequency and severity of cancer treatment-related symptoms, including nausea, diarrhea, and infection. Measure: Patient-reported symptom frequency and severity scores
Time frame
5 Months3
Cancer Treatment Adherence and Duration
Adherence to prescribed cancer therapy and treatment duration. Measure: Rates of dose reductions, early treatment discontinuation, and treatment duration
Time frame
5 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
VERIS HEALTH INC
Lead sponsor
National Institutes of Health (NIH)
Collaborator
National Institute on Minority Health and Health Disparities (NIMHD)
Collaborator
The Ohio State University Comprehensive Cancer Center
Collaborator
Source ClinicalTrials.gov